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Abstract
Hepatoid carcinoma of the ovary (HCO), a rare invasive malignant tumor composed mainly of epithelioid cells,
presented with unilateral or bilateral ovarian masses and elevated serum α-fetoprotein (AFP), has been found
mainly in post-menopausal women. We hereby report on the case of a 53-year-old Chinese woman who presented
with abdominal distension and a lower abdominal mass with high serum levels of CA-125 and AFP. She was later
diagnosed with bilateral HCO. After surgery and following chemotherapy, the patient had no recurrence of tumor
or ascites. The hepatoid cells were positive for AFP, p53 and CK7 by immunohistochemistry. Her serum CA-125 and
AFP levels had decreased significantly after surgery. Our results suggest that testing and monitoring of serum levels
of AFP and CA-125 are considered as potential biomarkers in the diagnosis and progression of this malignancy, and
that tissue immunohistochemical staining for AFP, p53 and CK7, plays an important role in distinguishing HCO from
other ovarian tumors.
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Background
Hepatoid carcinomas are less frequently occurring tumors of
the stomach, lungs, kidneys, endometrium and ovaries, with
pathological features similar to those of hepatocellular carcin-
oma (HCC). Hepatoid carcinoma of the ovary (HCO) is a very
rare type of high-grade, invasive malignant ovarian tumor
composed mainly of epithelioid cells. This malignancy has
been reported mainly in post-menopausal women presenting
with unilateral or bilateral ovarian masses and elevated serum
level of α-fetoprotein (AFP). Microscopically, these tumors are
characterized by solid sheets of large cells with abundant eo-
sinophilic cytoplasm, centrally pleomorphic nuclei and distinct
cellular borders. The tumor cells are diffusely immunoreactive
for AFP. To date, only 20 patients with diagnosis of HCO have
been reported. We describe here the case of a 53-year-old
Chinese woman diagnosed with a primary HCO, the clinical
and pathological characteristics are also briefly discussed.
Case presentation
A 53-year-old Chinese woman was admitted to our hos-
pital due to abdominal distension for 1 month and a
lower abdominal mass for 10 days. She was diagnosed
with hysteromyoma and underwent a sub-total hysterec-
tomy. There was no familial history of gynecological dis-
ease. Her father died of liver disease. Pelvic examination
revealed two palpable, connected masses, irregular in
shape, tender to touch and measuring 8×6×4 cm. Color
Doppler ultrasound showed that the uterus was absent
and the cervical stump was smooth. Two heterogeneous
hypoechoic foci of irregular shape were observed in the
uterus, one measuring 9.2×7.1 cm in the right adnexa
and the other measuring 8.0×6.7 cm in the left adnexa.
A computed tomography (CT) scan of the abdomen
showed two soft tissue masses in the pelvic cavity, meas-
uring 7.4×6.4 cm and 8.0×4.6 cm. No abnormalities were
seen in the bladder, liver, cervical stump or rectum
(Figure 1). Her serum CA-125 level was 124.60 U/mL
(normal <35 U/mL) and her serum AFP concentration
was 761.20 ng/mL (normal <7.0 ng/mL). Her serum
levels of carcinoembryonic antigen (CEA), CA-199, es-
tradiol and testosterone, were within normal ranges.
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She was diagnosed with an ovarian malignant tumor
and underwent bilateral adnexa dissection, greater
omentum dissection and dissection of metastatic
nodules on the mesentery. About 40 mL of pale yellow
liquid was found in the abdominal cavity. On gross
examination, the right ovary was enlarged to 9×7×6 cm
and the left ovary to 7×7×6 cm, with both ovaries irregu-
lar in shape. Several cauliflower lesions were presented
on the surface of both ovaries, with several hard, white
nodules, measuring 5 to 20 mm in diameter, on the sur-
face of the greater omentum and mesentery. The cut
surface of the tumor was mostly solid and yellow-brown,
Figure 1 Abdominal CT scans in the patient. Abdominal CT scan was performed in the patient and showed two soft tissue masses in the
pelvic cavity (one measuring 7.4×6.4 cm and the other measuring 8.0×4.6 cm). No abnormalities were seen in the bladder, liver, cervical stump or
rectum. The arrows indicated the messes.
Figure 2 Light microscopic examination of the tumor cells. The tumors removed were processed and slides were washed and
counterstained with H&E stain (200x), observed under light microscopy showing polygonal and oval in shape. The tumors were composed of
sheets, nests and trabeculae of cells with distinct borders and containing moderate to abundant amounts of eosinophilic cytoplasm. The nuclei
were oval and located in the center of the cells. The arrows indicate the tumor cells.
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with several gray-white hard nodules on the surface of
the greater omentum. The surface of liver was negative
for metastasis.
Light microscopic examination showed that the tumor
cells were polygonal and oval in shape and that the
tumors were composed of sheets of cells with moderate
to abundant amounts of eosinophilic cytoplasm. The nu-
clei were oval and located at the center of the cells. Most
tumor cells had distinct borders and were arranged in
sheets, nests or trabeculae (Figure 2). Paraffin tissue
blocks were prepared and stained with hematoxylin-
eosin and antibodies to AFP, AAT, CD99, CEA, poly-
clonal CEA, CA-125, HCG, α-inhibin, CK7, CK8, CK20,
EMA, CD10 and WT1. The results showed that hepa-
toid cells were positive for AFP, p53 and CK7 and focally
positive for α-inhibin, but negative for CK20, CDX-2,
Vimentin, CA-125, OCT3/4, NSE, hepatocyte paraffin 1,
WT1, PLAP, AG/AG, polyclonal CEA, EMA, CD10 and
CgA (Figure 3). The percentage of tumor cells that were
positive for CK7 was greater than 90%. In contrast, less
than 10% of tumor cells were positive for AFP. She was
later confirmed with bilateral HCO with involvement of
the greater omentum.
Seven days after surgery, she was started on chemo-
therapy with paclitaxel and carboplatin, administered
once every 21 days. Three weeks later, serum levels of
CA-125 and AFP decreased to 55.75 U/mL and 120.30
ng/mL, respectively. She received a total of 6 cycles of
chemotherapy. Follow-up examination with color Dop-
pler ultrasound of the abdomen and pelvic cavity 15
months after treatment showed no recurrence of tumor
and ascites. Her serum CA-125 and AFP levels decreased
to 10.87 U/mL and 113.30 ng/mL, respectively.
Discussion
The first case of HCO was described in 1987. Originally,
HCO, a rare ovarian tumor that usually presents with
signs and symptoms of an adnexal mass, such as
Figure 3 Immunohistochemical staining of AFP, p53, CK7 and α-inhibin in tumor cells. Tumor tissues were inflated, fixed in formalin,
paraffin-embedded and sectioned for histological analysis. Slides were washed and counterstained with antibodies to AFP, p53, CK7 and α-inhibin
using immunohistochemistry staining kits (Maxin BIO, Fu Zhou, China). The results showed that the hepatoid cells were focally positive for AFP
(A), positive for p53 (B) and CK7 (C), and α-inhibin (D)) (Original magnification, 200x).
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progressive abdominal distension and lower abdominal
pain, has been described in only post-menopausal
women aged from 42 to 78 years (average, 63 years) [1].
It can also be detected as an asymptomatic unilateral
ovarian mass (rarely bilateral). This malignancy mostly
was found at an advanced clinical stage and progresses
rapidly, with metastases to the abdomen and occasion-
ally to the lungs; with median survival about 2 years [2].
Macroscopically, HCOs are solid and cystic with a size
of 20 cm in the greatest diameter. Histologically, HCO
resembles HCC, which are composed of solid sheets or
aggregates of uniform cells with moderate and abundant
acidophilic cytoplasm, distinct cell borders and centrally
located, prominent nuclei. Mitoses, some even atypical,
are frequent [3]. HCO is associated with elevated serum
AFP and CA-125 levels. At diagnosis, our patient had
serum CA-125 concentration of 124.60 U/mL and AFP
concentration of 761.20 ng/mL. After the first cycle of
chemotherapy, the CA-125 and AFP levels decreased to
55.75 U/mL and 120.30 ng/mL, respectively. After 15
months and 6 cycles of chemotherapy, they both
reduced to 10.87 U/mL and 113.30 ng/mL, this sug-
gested that follow-up by monitoring serum AFP and
CA-125 levels was an important prognostic indicator in
this patient. Immunohistochemical staining showed this
tumor to be positive for AFP, CEA and cytokeratin. Al-
though the tumor was negative for EMA and CD10,
which may show a canalicular pattern, this type of stain-
ing is not essential for diagnosis of hepatoid carcinoma
and our clinical, morphological and immunohistochem-
ical findings collectively support the diagnosis.
Normal hepatocytes, bile duct epithelium and HCCs
are focally positive for CK18, as shown in HCOs. In con-
trast, CK19 and CK20 are expressed in normal gastro-
intestinal epithelial cells, bile duct cells and some
adenocarcinomas including ovarian surface epithelial
carcinomas, but not in normal hepatocytes and HCCs
[4]. The CK profile of HCO differed from that of normal
and neoplastic hepatocytes, but was similar to that of
common epithelial adenocarcinomas, which were posi-
tive for CK19 and CK 20, suggesting that HCOs might
come from epithelial origin [5]. Study of the expression
of hepatocyte paraffin 1, which reacted with normal and
neoplastic hepatocytes in ovarian tumors with hepatoid
differentiation, showed that expression of this protein
was correlated with the degree of hepatoid differenti-
ation [4]. Thus, diagnosis of HCO was based on histo-
pathological findings, immunohistochemical staining
patterns and marked elevation of AFP.
Differential diagnosis of HCO includes yolk sac tumors
of the ovary and endometrial carcinomas. Yolk sac
tumors of the ovary are rare but highly likely to be ma-
lignant, and are often bulky and increase rapidly in size.
They express high amounts of AFP, which increases with
tumor progression. Yolk sac tumors of the ovary are dif-
ficult to diagnose. Thus, multiple examinations of patho-
logical slides are needed to ensure that these are not
mixed tumors, especially tumors containing teratomas
[6]. In the clinical setting, the presence of these globules,
along with the production of AFP, can be diagnosed as
yolk sac tumors of the ovary. Endometrial adenocarcin-
omas rarely produce AFP. Microscopically, endometrial
adenocarcinomas are usually composed of a major me-
dullary portion and a minor tubular adenocarcinoma in-
vading the myometrium, myometrial lymphatics and
blood vessels. Vascular permeation by neoplastic cells
was prominent and extensive hepatoma-like features
were often observed [7].
To date, there is insufficient data regarding the opti-
mal treatment of patients with HCO. Most patients are
treated by surgery, followed by a chemotherapy regimen
similar to those used in patients with ovarian-like car-
cinomas. HCOs are highly aggressive, with 75% of
patients presenting with stage III or IV diseases. For
these patients, the initial step in patient management is
reduction of the surgical bulk, followed by chemother-
apy. In this case, the current treatment of choice for ini-
tial chemotherapy is six cycles of paclitaxel plus
carboplatin. Additional efficacy may be provided by
intraperitoneal chemotherapy through the combination
of new cytotoxic agents with paclitaxel and carboplatin,
and integrating biological agents into front-line therapy
[8]. Even after surgery and ovarian-like cancer chemo-
therapy regimens, such as carboplatin and paclitaxel,
most patients showed limited responses. Patients with
immunological disorders tend to have a poor tolerance
to chemotherapy and short survival, as reported in a 46-
year-old African-American woman with HCO and sys-
temic lupus erythematosus [4]. Our patient was treated
with surgery followed by a total of six cycles of paclitaxel
and carboplatin chemotherapy. We found that this regi-
men was well tolerated and toxicities were manageable.
Follow-up color Doppler ultrasound examination of the
abdomen and pelvic cavity in this patient showed no evi-
dence of tumor recurrence or ascites 15 months after
initial diagnosis.
Conclusions
In summary, we report a rare case of HCO in a 53-year-
old Chinese woman. Our results show that surgery
followed by administration of a total of six cycles of
paclitaxel and carboplatin chemotherapy, was a reason-
able approach for this patient. Examination of the serum
AFP and CA-125 levels is important for the diagnosis
and prognosis of this disease. In addition, immunohisto-
chemical staining for AFP, p53 and CK7 are helpful in
distinguishing HCOs from other ovarian tumors with
hepatoid features.
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